Nu Skin 2010 Annual Report - Direct Selling News

More documents

Recommendations

Info

$163M AGELOC GALVANIC SPA AND GELS $210M AGELOC TRANSFORMATION PRODUCTS $37M AGELOC VITALITY 2010 ageLOC sales 6
2 AN INNOVATIVE AND EXCLU- SIVE ANTI-AGING PORTFOLIO The second factor contributing to our continued success is our innovative anti-aging product pipeline. We continue to believe, and science continues to confirm, that the future of anti-aging technologies lies within the human genome. Based on decades of science, we are elevating anti-aging technology by targeting the sources of aging. Our proprietary ability to identify, target and reset groups of agerelated genes to more youthful activity levels continues to be well received in the marketplace, and is consistently validated scientifically. During 2010, our scientists were invited to give more than 20 presentations at 11 different academic conferences around the world. These presentations discussed the genetic basis of aging and the identification of nutritional interventions that target aging at its source and promote healthy life span. We are in the very early days of scientific discoveries on this front, and will continue to broaden our reach in taking this message to Targeting aging at its source. consumers around the world. In 2010, we provided a glimpse of ageLOC’s potential with the highly successful global rollout of the ageLOC Transformation skin care system. The Transformation System generated about $210 million of revenue in 2010—a remarkable number for the first year of sales. Add to this the sales from the Galvanic Spa and related gels and 2010 ageLOC skin care revenue was approximately $410 million, or 27 percent of our total annual revenue. We are pleased with these initial ageLOC results and believe it reflects the great market demand that is possible for our ageLOC antiaging portfolio. In 2011, we are infusing ageLOC science into our nutritional product offering. We have a solid base to work from when it comes to nutrition, with more than 40 percent of our revenue coming from our Pharmanex ® nutrition line. In the fourth quarter of 2010, sales of our flagship nutrition product LifePak ® increased 6 percent, despite the fact that the bright lights have really been focused on the skin care side of our business. In the latter half of the year, we took ageLOC ‘inside’ with the introduction of ageLOC Vitality in the United States and Japan, and in the fall of this year we will initiate the global launch of a new blockbuster supplement that features ageLOC science and proven anti-aging benefits. We are optimistic that the introduction of ageLOC into our Pharmanex product line will enable us to sustain growth in 2011. INNOVATE A REVOLUTIONARY DISCOVERY With exclusive access to 30 years of genetic anti-aging research, Nu Skin’s scientific team has identified key groups of age-related genes called Youth Gene Clusters that influence how we age. Nu Skin’s proprietary ageLOC ® science identifies, targets, and resets these Youth Gene Clusters to a more youthful gene expression pattern. 7
Page 1: NU SKIN ANNUAL REPORT 2010 ELEVATE
Page 4 and 5: 35,676 32,939 30,588 30,002 2007 20
Page 6 and 7: BUILDING FOR THE FUTURE In 2011, we
Page 10 and 11: 8 8
Page 12 and 13: 5 INCREASING OPERATIONAL EFFICIENCI
Page 14 and 15: * GAAP RECONCILATION TABLE 2007 200
Page 17 and 18: Can we sustain growth? Yes we can.
Page 19 and 20: UNITED STATES SECURITIES AND EXCHAN
Page 21 and 22: TABLE OF CONTENTS PART I 1 ITEM 1 B
Page 23 and 24: PART I ITEM 1. BUSINESS OVERVIEW We
Page 25 and 26: The following table summarizes our
Page 27 and 28: Other. We also offer a limited numb
Page 29 and 30: introduction of additional ageLOC a
Page 31 and 32: ness model utilizing sales employee
Page 33 and 34: in a manner to attract the general
Page 35 and 36: take longer than we anticipated. Pl
Page 37 and 38: chases, management services and con
Page 39 and 40: These declines could continue or in
Page 41 and 42: ous markets, including Japan, South
Page 43 and 44: creased scrutiny by the government.
Page 45 and 46: pact the cost associated with manuf
Page 47 and 48: on a sustained basis. Factors that
Page 49 and 50: negotiated contracts with shipping
Page 51 and 52: System failures could harm our busi
Page 53 and 54: consumption taxes based on an audit
Page 55 and 56: STOCK PERFORMANCE GRAPH Set forth b
Page 57 and 58: ITEM 7. MANAGEMENT’S DISCUSSION A
Page 59 and 60:
estrictions on the importation of f
Page 61 and 62:
RESULTS OF OPERATIONS The following
Page 63 and 64:
South Asia/Pacific. The following t
Page 65 and 66:
employees in Mainland China who had
Page 67 and 68:
We currently have debt pursuant to
Page 69 and 70:
the legal form of the transaction.
Page 71 and 72:
closures related to vendor’s mult
Page 73 and 74:
NU SKIN ENTERPRISES, INC. Consolida
Page 75 and 76:
NU SKIN ENTERPRISES, INC. Consolida
Page 77 and 78:
NU SKIN ENTERPRISES, INC. Notes to
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Report of Independent Registered Pu
Page 101 and 102:
PART III The information required b
Page 103 and 104:
corporated by reference to Exhibit
Page 105 and 106:
*10.56 Form of 2010 Plan Director S
Page 107 and 108:
BOARD OF DIRECTORS Blake M. Roney E
Page 109:
18 NU SKIN ENTERPRISES, INC. 75 WES
show all

Nu Skin 2010 Annual Report - Direct Selling News

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?